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Abstract: 
Objective: We previously developed a predictive model to assess the risk of developing acute pancreatitis (AP) in 
patients with severe hypertriglyceridemia (HTG). In this study, we aimed to externally validate this model.  
Methods: The validation cohort included cross-sectional data between 2013 and 2017. Adult patients (≥18 years-
old) with triglyceride levels ≥ 1,000 mg/dL were identified. Based on our previous four factors-predictive model 
(age, TG, excessive alcohol use, and gallstone disease), we estimated the probability of developing AP. Model 
performance was assessed using area under receiver operating characteristic curve (AUROC). 
Results: In comparison to the original cohort, patients in the validation cohort had more prevalent acute pancreatitis 
(16.2% vs 9.2%, p<0.001) and gallstone disease (7.5% vs 2.1%, p<0.001). Other characteristics were comparable 
and not statistically significant. The AUROCs were almost identical: 0.8337 versus 0.8336 in the validation and the 
original cohorts respectively. In univariable analyses, the highest increase in odds of AP was associated with HTG, 
followed by gallstones, excessive alcohol use, and younger age.  
Conclusion: This study externally validates the four-factor predictive model to estimate the risk of AP in adult 
patients with severe HTG (TG ≥ 1,000 mg/dL). Younger age was confirmed to place patients at high risk of AP.  
The clinical risk categories suggested in this study may be useful to guide treatment options.  
Funding: none. 
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AP (acute pancreatitis), ASCVD (atherosclerotic cardiovascular disease), AUROC (area under receiver operating 
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INTRODUCTION 
Acute pancreatitis (AP) can be associated with severe complications, financial burden, negative impact on quality of 
life, and occasionally can be potentially life-threatening with significant morbidity (1). Severe hypertriglyceridemia 
(HTG), defined as TG ≥1000 mg/dL, is a well-described risk for AP, thought to be an etiological factor in 
approximately 10% of all AP patients (2). It is the third most common etiology after excessive alcohol intake and 
gallstone disease and is the most common etiological factor (up to 56%) of AP in pregnant women (3). HTG is a 
frequently silent disease with several possible etiologies including genetic (like lipoprotein lipase deficiency and 
apolipoprotein CII deficiency), plurigenetic, and secondary disorders (such as obesity, diabetes, alcohol, pregnancy, 
and certain medications) (4-6). HTG is usually incidentally noted on screening lipid panel, occasionally by physical 
exam findings such as eruptive xanthomas, or first identified during hospitalization for AP (7). With adequate 
control of their triglycerides level (TG), the risk of future AP decreases significantly (4).  
The occurrence of AP in patients with HTG can vary based on certain patient characteristics (8). In a previous cross-
sectional study, we identified four significant clinical factors associated with the risk of developing AP: younger 
age, excess alcohol intake, gallstone disease, and severity of HTG (8). Although most of these risk factors are well-
recognized, there was no risk calculator to predict the probability of developing AP based on individual patient 
characteristics. Using these factors, we developed a predictive model to estimate the risk probability of occurrence 
of AP (9). This predictive model had an area under receiver operating characteristic (AUROC) curve of 0.8336 
indicating good predictability. Approaches for validation of predictive model include internal cross-validation or 
validation in separate external cohort. In this study, we aimed to externally validate this model using a different 
retrospective cross-sectional cohort matching the retrospective nature of the original study to assess its predictive 
utility (8). The use of an external cohort is an accepted method for validation and it was used in other predictive 
models like FRAX score (10). 
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MATERIALS AND METHODS 
Study design: 
This is a retrospective cross-sectional study spanning from April 2013 to May 2017 in an urban safety-net hospital 
in Chicago, Illinois. We aimed to externally validate the predictive model from our original study that spanned from 
January 2003 to March 2013 (8). No patients from the original study were included in this validation cohort. 
 
Variables: 
Inclusion criteria were adult patients (aged ≥18 years) with TG ≥ 1000 mg/dL at any point of time (i.e. whether as 
inpatient or outpatient) during the study period. Data were gathered via electronic medical chart review from the 
same healthcare system as the original cohort. We aimed to gather the significant variables based on our previous 
study along with the basic demographic data. The important variables collected were age, gender, self-identified 
race, TG level, cholelithiasis, excessive alcohol intake, and history of AP. We aimed to assess the risk of developing 
the first episode of acute pancreatitis only. Our results do not apply to the risk of recurrent AP. Diagnosis of HTG-
AP was based on the presence of TG ≥1000 mg/dL in addition to two out of the following three criteria (11): 
classical abdominal pain of AP, lipase level more than or equal three times the upper limit of normal, and evidence 
of AP on imaging studies like CT abdomen. If the patient had multiple TG levels, the TG level at the time of the AP 
episode was collected. If multiple episodes of AP occurred, only the data at the time of the initial episode were 
collected. In patients without AP, the highest level of TG was collected with age at time of collection used for 
analysis. Excessive alcohol intake was based on the documentation of heavy or binge alcohol drinking as defined by 
CDC as reported in our previous study (8). Cholelithiasis was based on imaging documentation of gallstones or gall 
bladder sludge. HTG severity was coded as a binary categorical variable: severe from 1,000 to 1999 mg/dL and very 
severe ≥2,000 mg/dL based on Endocrine Society guidelines (2). Those with very severe HTG (≥2,000 mg/dL) 
appear to be at highest risk for developing AP (2, 12). Our lab’s triglycerides assay is based on the enzymatic 
(Glycerol Phosphate Oxidase) method performed on Beckman Coulter Chemistry Analyzer, AU 5800. The 
instrument is equipped with methodology to ensure that the results are accurate when dealing with very high TG 
levels up to 20,000 mg/dL). Alcohol, cholelithiasis, alcohol abuse, and AP were expressed as binary variables, 
coded as ‘yes’ or ‘no’. Age was used a continuous variable, presented in years. Race was coded as: African 
American, Latino, Caucasian, Asian, and others. 
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Sample size estimation: 
Power analysis was performed to estimate sample size based on our original cohort. We used 2-sided comparison 
between means (for continuous variables) and proportions (for categorical variables), power of 0.90 and type I error 
of 5%. Prevalence of AP among HTG in the original cohort was 9.2% which was accounted for in the calculation. 
We estimated that 436, 398, and 276 patients would be adequate to detect significance for age, alcohol abuse, and 
severity of HTG respectively. On the other hand, 2,555 patients would be needed to detect significance for 
cholelithiasis. Based on this power estimate, we aimed for a minimum of 436 patients and we agreed that it would 
not be feasible to account for cholelithiasis. Database search identified 597 patients who were included in the study.  
 
Statistical Analysis: 
Descriptive statistics for categorical variables were reported as percentages and for continuous variables we used 
either mean ± standard deviation or median with interquartile range (IQR). To assess significance of association, χ
2
 
test was used for categorical variables and independent-samples t-test was used for continuous variables. Binary 
multivariable logistic regression was used to estimate odds ratios, confidence intervals, and p-values.  We predicted 
the risk probabilities for developing AP using the formula developed in our original study and mentioned below (8). 
Age is a continuous variable, presented in years. Presence of alcohol or gallstones was presented as ‘one’, and the 
absence was presented as ‘zero’. The presented of TG 1,000 to 1,999 was presented as ‘zero’ while TG ≥ 2,000 was 
presented as ‘one’. A receiver operating characteristic (ROC) curve was used afterwards to assess performance of 
the predicted probabilities as compared to the actual occurrence of AP. In addition, the ROC curve output was 
compared to the one created by the original model. A two-tailed p value < 0.05 is considered significant. 
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝐶𝐶𝑝𝑝𝑝𝑝𝐶𝐶𝑝𝑝𝐶𝐶𝑝𝑝 = 𝐸𝐸𝐸𝐸𝐸𝐸 (−1.960−0.069∗𝐴𝐴𝐴𝐴𝐴𝐴+1.362∗𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴ℎ𝐴𝐴𝐴𝐴+1.373∗𝐺𝐺𝐺𝐺𝐴𝐴𝐴𝐴𝐺𝐺𝐺𝐺𝐴𝐴𝐺𝐺𝐴𝐴𝐺𝐺+1.575∗𝑇𝑇𝐺𝐺 𝑑𝑑𝑑𝑑𝐴𝐴ℎ𝐴𝐴𝐺𝐺𝐴𝐴𝑜𝑜𝐴𝐴𝑜𝑜𝐺𝐺)
1+ 𝐸𝐸𝐸𝐸𝐸𝐸 (−1.960−0.069∗𝐴𝐴𝐴𝐴𝐴𝐴+1.362∗𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴ℎ𝐴𝐴𝐴𝐴+1.373∗𝐺𝐺𝐺𝐺𝐴𝐴𝐴𝐴𝐺𝐺𝐺𝐺𝐴𝐴𝐺𝐺𝐴𝐴𝐺𝐺+1.575∗𝑇𝑇𝐺𝐺 𝑑𝑑𝑑𝑑𝐴𝐴ℎ𝐴𝐴𝐺𝐺𝐴𝐴𝑜𝑜𝐴𝐴𝑜𝑜𝐺𝐺) 
We compared the original and validation cohorts by cohort level confidence intervals following fixed effects meta-
analysis concepts. For continuous variables, confidence intervals were calculated based on the sample size, standard 
deviation, and calculated standard error of the mean. For categorical variables, confidence intervals were calculated 
based on the proportion, sample size, calculated probability and standard error of the mean. The confidence intervals 
of different variables were compared for 95.0%, 99.0%, and 99.9% (13).  
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Statistical analysis was done using SPSS version 24 (IBM) and Microsoft Excel version 2016. There were no 
missing data and no sub-group analysis. The study was approved by the institutional review board of our institution.  
 
RESULTS 
Comparison of the baseline characteristics of the validation and original cohorts is shown in Table 1. In our initial 
study, 1157 patients met the inclusion criteria of being adult (aged ≥18 years) and having TG ≥1000 mg/dL between 
January 2003 and March 2013. In the current validation study, 597 patients were identified using the same criteria 
between April 2013 and May 2017.  We found significant difference in gallstone prevalence between the validation 
and original cohorts (7.5% versus 2.1%, P<0.001). In comparison of the groups with AP, the prevalence of AP was 
higher (16.2%) in the validation cohort compared to 9.2% in the original cohort, p<0.01. We did not find any other 
significant differences between the groups.  
 
Multivariable analysis for the four significant factors for developing AP in both cohorts is shown in Table 2. All the 
four independent risk factors had comparable odds ratios and confidence intervals. In comparison of patients 
between severe and very severe HTG, AP was 5.4- and 4.3-fold more prevalent among the latter group in both 
validation and original cohorts respectively. Patients who developed AP were younger in both cohorts. AP was 1.9- 
and 2.8-fold more prevalent in patients <50 years in the validation and original cohorts respectively.  
 
Excessive alcohol use was two folds higher in patients with AP as compared to those without in both cohorts (Table 
2). AP was more prevalent in males as compared to females in the validation and original cohorts (37.0% vs 16.0% 
and 34.7% vs 15.6% respectively). Excess alcohol use among ethnic groups was similar in both cohorts: African 
Americans (41.0% vs 41.0%), Latino (21.2% vs 24.8%), whites (35.5% vs 35.6%), Asians (18.2% vs 16.7%), and 
others (15.4% in 36.4%). Gallstone disease was 3.1- and 4.0-fold higher in patients with AP as compared to those 
without in the validation and original cohorts respectively. Gallstone disease was more common in females in both 
cohorts.  
 
The predicted model for developing AP using the formula developed in our original study achieved area under the 
receiver operating characteristic curve (AUROC) of 0.8337 (p<0.001) in this validation cohort as compared to 
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0.8336 in the original cohort as shown in Figure 1. To predict the risk of developing AP in the original study, we 
suggested three cut-off values: low risk <4.4%, intermediate risk 4.4-<12%, and high risk ≥12%. A cut-off of ≥ 
4.4% had sensitivity of 94.4% and specificity 52.9% in the original cohort versus 62.9% and 86.4% in the validation 
cohort respectively. A cut-off of ≥ 12% had sensitivity 71.0% and specificity 81.7% in the original cohort versus 
32.0% and 97.4% in the validation cohort respectively. Based on the data from the validation cohort, we propose a 
new low risk cut-off value of 1.4% with better sensitivity in both cohorts. A cut-off value of ≥ 1.4% has sensitivity 
98.1% and specificity of 15.4% in the original study versus 87.6% and 61.2% in the validation study respectively as 
shown in table 3. Clinical examples of risk categories are shown in table 4. 
 
DISCUSSION 
Predictive models are commonly used in clinical practice like the Fracture Risk Assessment Tool (FRAX) score to 
estimate the 10-year risk of fractures and the atherosclerotic cardiovascular disease (ASCVD) risk score to estimate 
the 10-year and lifetime risks for ASCVD (14, 15). The strength of the predictive model is based on the AUROC 
that reflects the accuracy of the model. AUROC of 0.9 to 1 is considered as ‘excellent’, 0.8 to 0.9 is ‘good’, 0.7 to 
0.8 is ‘fair’, 0.6 to 0.7 is’ poor’, and 0.5 to 0.6 is ‘fail’ (16). In a population-based cohort of 141,320 women, the 
AUROC for FRAX score in estimating major osteoporotic fractures was 0.65 and for estimating hip fractures was 
0.82 (10). The ASCVD risk score had AUROC of 0.71 to 0.82 in external validation studies in USA and Europe 
(17). When the ASCVD score was validated in an Asian population, which was underestimated in the original 
cohort, it yielded AUC of 0.63 (16). This highlights that caution should be used in applying predictive models in 
different ethnic groups.  
 
In this study, we externally validated our predictive model to estimate the probability of developing AP based on the 
four significant factors identified in our earlier study (age, excessive alcohol, gallstone disease, and severe HTG) 
(8). Both original and validation cohorts were similar in clinical features (age, gender, and ethnicity), and the 
prevalence of risk factors except for gallstone disease that was more prevalent in the validation cohort. The 
increased prevalence of acute pancreatitis in the validation cohort was possibly secondary to the increased 
prevalence of gallstone disease. In both cohorts, the highest odds ratio among the four risk factors was HTG 
followed by gallstones, excessive alcohol use, and age. Patients who developed AP were significantly younger in 
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both cohorts. Younger age had a strong impact on the predicted probability and a difference of 40 years in age can 
change the predicted probability up to 15 folds. It is unclear why younger patients are at increased risk to develop 
AP. Speculations include differences in protective factors, access to medical care, or lifestyle differences of those 
who develop AP at different ages.  
The predictive model performed strongly in both the original cohort and the current external validation one with 
AUROC of 0.8336 and 0.8337 respectively. Validated now externally, this is the first predictive model to help 
clinicians estimate the risk of AP in patients with severe HTG. The cut-off value of 12% for high-risk patients had a 
good specificity in both cohorts. In this study, we lowered the low risk category to <1.4% based on sensitivity and 
specificity. The proposed three risk categories may represent the following typical patients. Low risk category will 
include older patients (≥56 years) with TG ≥ 2000 mg/dL without alcohol and gallstones. Intermediate risk 
categories may include younger patients (≤33 years) with TG between 1000 to ≤1999 mg/dL and no other risk 
factors or older patients with TG ≥2000 mg/dL and one additional risk factor. High risk category would be younger 
patients (≤ 42 years) with TG ≥2000 mg/dL and one additional risk factor. For the older patients, to be in the high 
risk category, they need to have TG more than 2000mg/dL and have both gallstones and alcohol excess (see also 
Table 4).  
 
This study has some limitations, such as the cross-sectional design and the need for longer duration of follow-up. 
The majority of the patients were Latino and African American in both cohorts. Caucasians and Asians were 
inadequately represented. As shown with the ASCVD risk calculator, the AUC may not be the same for different 
ethnicities (15). This suggests that this predictive model may be useful mainly in Latino and African American 
patients. Further studies are needed in other populations to ensure its validity. The study was underpowered for 
cholelithiasis for feasibility. However, gallstones were shown to be a statistically significant risk factor. Due to the 
cross-sectional nature of our studies, we could not assess the time factor in predicting the risk of AP and may need 
further longitudinal studies to evaluate it. In addition, the predictive model was not tested for any mode of therapy 
and may need prospective studies to assess its utility regarding treatment and possible prevention of AP.  
 
In conclusion, this study validates our previous predictive model in adult patients with severe hypertriglyceridemia 
(TG ≥ 1,000 mg/dL). The four independent risk factors (age, excessive alcohol, gallstone disease, and severity of 
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hypertriglyceridemia) were validated. The age was shown to be a strong driver of the risk with being younger 
predicts much higher risk. Longitudinal studies utilizing this model and assessing impact of therapies may further 
enhance its clinical validity 
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Table 1 Baseline characteristics for all patients with severe HTG and in patients with and without pancreatitis in the original and validation studies 
Variable  
Validation Study Original Study 
P Value  
(B vs. E)* 
Total study 
population with 
TG > 1000 mg/dl 
(A) 
Patients who 
developed acute 
pancreatitis 
(B) 
Patients who did not 
develop acute 
pancreatitis 
(C) 
Total study 
population with TG 
> 1000 mg/dl 
(D) 
Patients who 
developed acute 
pancreatitis 
(E) 
Patients who did not 
develop acute 
pancreatitis 
(F) 
Patients (No. [%)) 597 (100.0) 97 (16.2) 500 (83.8) 1157 (100.0) 107 (9.2) 1050 (90.8) <0.01 
Age (y), mean + SD 46.5 (11.3) 41.8 (10.7) 47.4 (11.2) 49.2 (11.5) 41.3 (9.9) 50.0 (11.3) NS 
Male sex (No. [%]) 435 (72.9) 71 (73.2) 364 (72.8) 875 (75.6) 79 (73.8) 796 (75.8) NS 
Race (No. [%]) 
 African American 
 Latino 
 Caucasian 
 Asian 
 Others 
 
195 (32.7) 
294 (49.2) 
73 (12.2) 
24 (4.0) 
11 (1.8) 
 
27 (27.8) 
52 (53.6) 
14 (14.4) 
2 (2.1) 
2 (2.1) 
 
168 (33.6) 
242 (48.4) 
59 (11.8) 
22 (4.4) 
9 (1.8) 
 
366 (31.6) 
444 (38.3) 
242 (20.9) 
66 (5.7) 
39 (3.4) 
 
30 (28.0) 
47 (43.9) 
19 (17.8) 
7 (6.5) 
4 (3.7) 
 
336 (32.0) 
397 (37.8) 
223 (21.2) 
59 (5.6) 
35 (3.3) 
 
NS 
NS 
NS 
NS 
NS 
Alcohol use 187 (31.3) 54 (55.7) 133 (26.6) 348 (30.1) 62 (57.9) 286 (27.2) NS 
Gallstone disease 45 (7.5)*** 17 (17.5) 28 (5.6) 24 (2.1)*** 7 (6.5) 17 (1.6) NS 
TG**, median (IQR) 1501.0  
(1186.5-2174.0) 
3170.0  
(1759.0-4885.0) 
1401.0  
(1153.0-1896.5) 
1444  
(1196.5-1991.5) 
2394  
(1552-4339) 
1406  
(1180.7-1876.5) NS 
1,000-1,999 1287.0 (1115.0-1560.5) 
1437.0 
(1175.0-1748.0) 
1282.0 
(1108.8-1549.3) 
1301.0 
(1150.0-1538.0) 
1457.0 
(1187.0-1646.5) 
1297.0 
(1150.0-1525.0) NS 
≥2,000 3203.5 (2376.3-4567.5) 
3990.0 
(3030.8-5745.0) 
2720.0 
(2221.3-3581.5) 
2739.5 
(2273.8-3950.8) 
3807.0 
(2638.0-6054.0) 
2637.0 
(2231.0-3358.0) NS 
*P value between patients with acute pancreatitis in the original versus validation cohorts (shaded in gray) 
**Reference value for triglycerides is 30 to 150 mg/dL 
*** P value <0.001 between the prevalence of gallstones in the total original versus validation cohorts. Of notice. 
The confidence intervals of different variables for patients who developed acute pancreatitis in the original and validation studies were calculated for confidence intervals of 95.0%, 99.0%, and 99.9%. 
The statistical significance was calculated based on the means or proportions. 
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Table 2 Multivariable models for factors associated with acute pancreatitis in patients with severe hypertriglyceridemia 
Variable  
Validation Study Original Study 
P Value 
(C vs. 
F)*** 
Acute 
Pancreatitis 
(A) 
No Acute 
Pancreatitis 
(B) 
Final Model 
Adjusted OR (95% 
CI) ** 
(C) 
Adjusted  
P Value* 
Acute 
Pancreatitis 
(D) 
No Acute 
Pancreatitis 
(E) 
Final Model 
Adjusted OR (95% 
CI) ** 
(F) 
Adjusted  
P Value* 
Triglycerides ≥2000 mg/dL (%) 68.0% 20.4% 8.97 (5.30-15.19) <0.001 58.9% 21.2% 4.8 (3.1-7.4) <0.001 NS 
Gallstone disease (%) 17.5% 5.6% 5.27 (2.36-11.77) <0.001 6.5% 1.6% 3.9 (1.4-10.8) 0.008 NS 
Excessive alcohol use (%) 55.7% 26.6% 4.13 (2.45-6.97) <0.001 57.9% 27.2% 3.9 (2.5-6.0) <0.001 NS 
Age in years [mean (SD)] 41.8 (10.7) 47.4 (11.2) 0.95 (.93-.97) <0.001 41.3 (9.9) 50.0 (11.3) 0.93 (0.91-0.95) <0.001 NS 
Abbreviations: OR= Odds Ratio, CI= Confidence Interval, NS=Not significant (P>.05) 
Only variables with P-Value <0.1 in the univariable analysis were considered in the multivariable model 
* The model was adjusted for age (years), triglycerides (dichotomous: 1000-1999 and ≥2000 mg/dL), excessive alcohol use, and gallstone disease. 
***The confidence intervals overlap suggesting no significant difference in a conservative approach. 
 
Table 3 Suggested Cut-offs for risk stratification based on the proposed model 
  Validation Study Original Study 
 Sensitivity Specificity PPV NPV Sensitivity Specificity PPV NPV 
≥1.4% 87.6% 61.2% 30.5% 96.2% 98.1% 15.4% 10.6% 98.8% 
4.4% 62.9% 86.4% 47.3% 92.3% 94.4% 52.9% 17.0% 98.9% 
≥12.0% 32.0% 97.4% 70.5% 88.1% 71.0% 81.7% 28.3% 96.5% 
Abbreviations: PPV=positive predictive value; NPV: negative predictive value 
Based on this validation study, we propose a low risk cut-off <1.4%, intermediate risk 1.4%–12.0%, and high risk cut-off>12.0% for the development of acute pancreatitis based on the predictive risk 
model. The previous low risk cut-off in the original study (4.4%) did not perform well in the validation study.  
 
Table 4 Clinical examples for the suggested three risk categories 
 Typical Patients Predicted risk 
Low Risk (<1.4%) - 60 years-old patient with TG≥2000 mg/dL with no excess alcohol use or gallstone disease 1.1% 
Intermediate Risk (1.4% to <12%) - 30 years-old patient with TG=1500 mg/dL with no excess alcohol use or gallstone disease - 60 years-old patient with TG=3000 mg/dL, history of excess alcohol use and no gallstone disease 
1.7% 
4.0% 
High Risk (≥12.0%) - 30 years-old patient with TG=2500 mg/dL, history of excess alcohol use and no gallstone disease - 60 years-old patient with TG=3000 mg/dL, history of excess alcohol use and presence of gallstone disease 
25.0% 
14.2% 
Abbreviations: TG=triglycerides. 
Predicted risk was calculated using our predictive model based on the risk factors mentioned in the corresponding row. 
External Validation – Hypertriglyceridemic Acute Pancreatitis     
 
 
 
Figure 1 AUROC curve for our predictive model in the original and validation cohorts 
Legend Figure 1: The orange solid line represents the area under receiver operating characteristic curve (AUROC) for the predictive model in the 
original cohort while the blue broken line represents the validation cohort. The strength of the predictive model is based on the AUROC that 
reflects the accuracy of the model. AUROC of 0.9 to 1 is considered as ‘excellent’, 0.8 to 0.9 is ‘good’, 0.7 to 0.8 is ‘fair’, 0.6 to 0.7 is’ poor’, and 
0.5 to 0.6 is ‘fail’ (16). 
